Tobacco

22nd Century

22nd Century released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 4.105 M (forecast USD 4.61 M), actual EPS USD -18.0836 (forecast USD -1.2)

22nd Century to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 4.61 M, EPS USD -1.2

22nd Century released FY2025 annual earnings on March 26 Pre-Market EST, actual revenue USD 7.049 M (forecast USD 18.1 M), actual EPS USD -52.8774 (forecast USD -9)

22nd Century released FY2025 Q4 earnings on March 26 Pre-Market (EST), actual revenue USD 1.048 M (forecast USD 4.05 M), actual EPS USD -15.731 (forecast USD -2.1)

22nd Century to release FY2025 Q4 earnings report on March 31, pre-market EST, with forecast revenue of USD 4.05 M and EPS of USD -2.1

22nd Century released FY2025 9 Months Earnings on November 4 Pre-Market EST, actual revenue USD 6.001 M, actual EPS USD -180.8722

22nd Century released FY2025 Q3 earnings on November 4 Pre-Market EST, actual revenue USD 4.011M, actual EPS USD 1.5499

22nd Century FY2025 Q3 Earnings Release on November 4, 2025 Pre-Market EST

22nd Century released FY2025 Semi-Annual Earnings on August 14 Pre-Market (EST), with actual revenue of USD 4.503 M and EPS of USD -710.6762

22nd Century released FY2025 Q2 earnings on August 14 Pre-Market (EST), actual revenue USD 2.228 M, actual EPS USD -204.1219

22nd Century to Release FY2025 Q2 Earnings Report on August 14, Pre-Market EST

22nd Century Group Collaborates with Tobacco Brands to Promote Low Nicotine Cigarettes

22nd Century Group Announces Progress in VLN® MRTP Renewal

22nd Century Group Reaches Expansion Agreement with Convenience Store Chain

22 Century Group Reports 48% Q1 2025 Revenue Growth

22nd Century released FY2025 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 2.275 M, actual EPS USD 0

22 Century Group Reports Projected Quarterly Loss of 87 Cents Per Share

22nd Century to Release FY2025 Q1 Earnings Report on May 13, Pre-Market EST

22nd Century released FY2024 earnings on March 20 Pre-Market (EST), actual revenue USD 11.88 M (forecast USD 33.53 M), actual EPS USD 0 (forecast USD -924.05 K)

22nd Century released FY2024 Q4 earnings on March 20 Pre-Market (EST), actual revenue USD 1.841 M (forecast USD 8.907 M), actual EPS USD 0 (forecast USD -223.56 K)

Liminatus Pharma

Agape ATP

Co-Diagnostics

NewGenIvf

Tradr 2X Long RGTI Daily ETF

Sunshine Biopharma

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Wheeler Real Estate

Defiance 2X Daily Long Pure Quantum ETF

XXII

22nd Century Group rose 12.92%; Philip Morris rose 0.34%, with a transaction volume of $340 million; Altria Group rose 0.29%, with a transaction volume of $242 million; British American Tobacco rose 1.63%, with a transaction volume of $158 million; FogCore Technology rose 0.93%, with a market value of $2.665 billion

Price Alert

Phillip Morris

Altria

British American Tobacco

RLX Tech

U.S. stock market update: 22nd Century Group rises 12.92%, new products boost brand expansion, optimistic market outlook but beware of volatility risks

XXII has launched a new product to expand the reach of its rapidly growing Pinnacle brand, enhancing brand strength and driving increased revenue and margin growth. This strategic move aims to open new retail opportunities and solidify the company's growth trajectory.

Unusual Whales

22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers

22nd Century Group (Nasdaq: XXII) is launching its Pinnacle VLN® cigarette brand in over 150 stores in metro New York and northern New Jersey. This expansion aims to capture a significant adult-smoker market, enhancing consumer access to low nicotine products. The rollout is part of the company's growth strategy, supported by FDA authorization for VLN® products, which contain 95% less nicotine. CEO Larry Firestone emphasized the importance of this milestone for revenue growth and market visibility.

StockTitan

22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand  | XXII Stock News

LABU

SBIO

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review | XXII Stock News

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review | XXII Stock News

Earnings Watch

22nd Century | 10-Q: FY2026 Q1 Revenue: USD 4.105 M

22nd Century | 8-K: FY2026 Q1 Revenue: USD 4.105 M

22nd Century Group shares are trading lower after the company annoucned it filed a prospectus to sell up to $6.4 millions shares under a sales agreement.

benzinga_article

22 世纪集团（XXII.US）现价 $1.420，当日 -8.97%，盘中 5 分钟跌幅跌破-3%，市值 0.01 亿。公司专注烟草减害技术，VLN®系列减害产品为核心。近日公布 2026 年产品增长战略计划，但短线资金仍选择高位回吐，市场关注该战略执行效果。

Movers Alert